{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:58:09Z","timestamp":1793915889580,"version":"4.8.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cannabinoids have potential efficacy as prophylaxis for chemotherapy-induced nausea and vomiting (CINV), but no recent meta-analysis has reported on their relative efficacy compared to other antiemetics. The aim of this meta-analysis is to examine the relative efficacy of cannabinoids for prophylaxis of CINV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A literature search was conducted in OVID Medline, EMBASE, and Cochrane Central Register of Controlled Trials from inception up until March 2024. Articles were included if they reported on complete response, no nausea, no vomiting or no use of rescue medications, and were randomized controlled trials with cannabinoids in one arm. Meta-analysis was conducted for each endpoint and for a composite endpoint amalgamating existing endpoints. Subgroup analyses by medication used in control arm and by study design were conducted. Cumulative and leave-one-out analysis was also conducted. Type I error was set at 0.05.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 26 studies were included in this meta-analysis, of which 23 were published before the 2000s. Nearly half of the included studies had some concern for bias. Cannabinoid had superior overall CINV control compared to placebo (RR 2.65, 95% CI 1.70\u20134.12, <jats:italic>I<\/jats:italic>\n              <jats:sup>2<\/jats:sup>\u2009=\u20090.00%). However, there was no difference between cannabinoid and active treatment alternatives (most using dated single-agent regimens) for any outcomes. A recent phase II\/III trial demonstrated superior efficacy of THC:CBD for secondary prevention of CINV when used as adjunctive therapy alongside modern antiemetic regimens, albeit mostly without olanzapine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>There is scant evidence for efficacy of cannabinoids for CINV in the era of triple and quadruple antiemetics. Although THC:CBD showed promised in a recent trial, further trials should examine its safety and efficacy in the context of regimens containing olanzapine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09251-w","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T17:32:11Z","timestamp":1739554331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting\u2014a systematic review and meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Ronald","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Prsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"5","key":"9251_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting\u2014incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503","journal-title":"Support Care Cancer"},{"issue":"14","key":"9251_CR2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374(14):1356\u20131367","journal-title":"N Engl J Med"},{"issue":"8","key":"9251_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00520-023-07978-y","volume":"31","author":"R Chow","year":"2023","unstructured":"Chow R, Yin LB, Baqri W et al (2023) Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)\u2014a systematic review and individual patient data meta-analysis. Support Care Cancer 31(8):505","journal-title":"Support Care Cancer"},{"issue":"4","key":"9251_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s005200050078","volume":"5","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5(4):307\u2013313","journal-title":"Support Care Cancer"},{"issue":"1","key":"9251_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/apm.2016.10.01","volume":"6","author":"S Ahrari","year":"2016","unstructured":"Ahrari S, Chow R, Goodall S, DeAngelis C (2016) Anticipatory nausea: current landscape and future directions. Ann Palliat Med 6(1):1\u20132","journal-title":"Ann Palliat Med"},{"issue":"2","key":"9251_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10549-015-3669-8","volume":"155","author":"T Ng","year":"2016","unstructured":"Ng T, Mazzarello S, Wang Z et al (2016) Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. Breast Cancer Res Treat 155(2):337\u2013344","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"9251_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00520-014-2392-z","volume":"23","author":"TA Santana","year":"2015","unstructured":"Santana TA, Trufelli DC, de Matos LL, Cruz FM, Del Giglio A (2015) Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer 23(1):213\u2013222","journal-title":"Support Care Cancer"},{"key":"9251_CR8","doi-asserted-by":"crossref","unstructured":"Chow R, Warr DG, Navari RM, et al. 2018 Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. J Hospital Manag Health Policy. 2","DOI":"10.21037\/jhmhp.2018.04.05"},{"issue":"8","key":"9251_CR9","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-018-4237-7","volume":"26","author":"R Chow","year":"2018","unstructured":"Chow R, Warr DG, Navari RM et al (2018) Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer 26(8):2519\u20132549","journal-title":"Support Care Cancer"},{"key":"9251_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.critrevonc.2019.07.017","volume":"142","author":"R Chow","year":"2019","unstructured":"Chow R, Aapro M, Navari RM et al (2019) Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol 142:164\u2013186","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"9251_CR11","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M et al (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29(7):3439\u20133459","journal-title":"Support Care Cancer"},{"issue":"2","key":"9251_CR12","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00520-021-06606-x","volume":"30","author":"R Chow","year":"2022","unstructured":"Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH (2022) Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer 30(2):1015\u20131018","journal-title":"Support Care Cancer"},{"issue":"1","key":"9251_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/ijms25010074","volume":"25","author":"PP Bathula","year":"2023","unstructured":"Bathula PP, Maciver MB (2023) Cannabinoids in treating chemotherapy-induced nausea and vomiting, cancer-associated pain, and tumor growth. Int J Mol Sci 25(1):74","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9251_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00520-022-07480-x","volume":"31","author":"B Alderman","year":"2022","unstructured":"Alderman B, Hui D, Mukhopadhyay S et al (2022) Multinational Association of Supportive Care in Cancer (MASCC) expert opinion\/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer. Support Care Cancer 31(1):39","journal-title":"Support Care Cancer"},{"issue":"5","key":"9251_CR15","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00520-019-05280-4","volume":"28","author":"R Chow","year":"2020","unstructured":"Chow R, Valdez C, Chow N et al (2020) Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting\u2014a systematic review and meta-analysis. Support Care Cancer 28(5):2095\u20132103","journal-title":"Support Care Cancer"},{"key":"9251_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"9251_CR17","doi-asserted-by":"crossref","unstructured":"McGuinness LA, Higgins JPT. 2020 Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods. n\/a(n\/a)","DOI":"10.1002\/jrsm.1411"},{"issue":"16","key":"9251_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJM197510162931603","volume":"293","author":"SE Sallan","year":"1975","unstructured":"Sallan SE, Zinberg NE, Frei E 3rd (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293(16):795\u2013797","journal-title":"N Engl J Med"},{"issue":"6","key":"9251_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/0003-4819-91-6-819","volume":"91","author":"AE Chang","year":"1979","unstructured":"Chang AE, Shiling DJ, Stillman RC et al (1979) Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. Ann Intern Med 91(6):819\u2013824","journal-title":"Ann Intern Med"},{"issue":"12","key":"9251_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.5694\/j.1326-5377.1979.tb127271.x","volume":"2","author":"H Ekert","year":"1979","unstructured":"Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P (1979) Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydro-cannabinol. Med J Aust 2(12):657\u2013659","journal-title":"Med J Aust"},{"issue":"6","key":"9251_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","volume":"91","author":"S Frytak","year":"1979","unstructured":"Frytak S, Moertel CG, O\u2019Fallon JR et al (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. Ann Intern Med 91(6):825\u2013830","journal-title":"Ann Intern Med"},{"issue":"23","key":"9251_CR22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJM197906073002302","volume":"300","author":"TS Herman","year":"1979","unstructured":"Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300(23):1295\u20131297","journal-title":"N Engl J Med"},{"issue":"11","key":"9251_CR23","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/archinte.1980.00330220019010","volume":"140","author":"LE Orr","year":"1980","unstructured":"Orr LE, McKernan JF, Bloome B (1980) Antiemetic effect of tetrahydrocannabinol: compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 140(11):1431\u20131433","journal-title":"Arch Intern Med"},{"issue":"2\u20133","key":"9251_CR24","first-page":"219","volume":"64","author":"N Steele","year":"1980","unstructured":"Steele N, Gralla RJ, Braun DW Jr, Young CW (1980) Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 64(2\u20133):219\u2013224","journal-title":"Cancer Treat Rep"},{"issue":"7","key":"9251_CR25","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4","volume":"47","author":"AE Chang","year":"1981","unstructured":"Chang AE, Shiling DJ, Stillman RC et al (1981) A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47(7):1746\u20131751","journal-title":"Cancer"},{"issue":"S1","key":"9251_CR26","doi-asserted-by":"publisher","first-page":"38S","DOI":"10.1002\/j.1552-4604.1981.tb02571.x","volume":"21","author":"JA Neidhart","year":"1981","unstructured":"Neidhart JA, Gagen MM, Wilson HE, Young DC (1981) Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 21(S1):38S-42S","journal-title":"J Clin Pharmacol"},{"issue":"Suppl B","key":"9251_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0305-7372(82)80032-7","volume":"9","author":"R Johansson","year":"1982","unstructured":"Johansson R, Kilkku P, Groenroos M (1982) A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 9(Suppl B):25\u201333","journal-title":"Cancer Treat Rev"},{"issue":"Suppl B","key":"9251_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0305-7372(82)80034-0","volume":"9","author":"JK Wada","year":"1982","unstructured":"Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE (1982) Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev 9(Suppl B):39\u201344","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"9251_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/bjc.1983.247","volume":"48","author":"S Ahmedzai","year":"1983","unstructured":"Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid in lung cancer chemotherapy. Br J Cancer 48(5):657\u2013663","journal-title":"Br J Cancer"},{"issue":"8","key":"9251_CR30","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/0277-5379(83)90032-9","volume":"19","author":"AW Hutcheon","year":"1983","unstructured":"Hutcheon AW, Palmer JB, Soukop M et al (1983) A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol 19(8):1087\u20131090","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"4","key":"9251_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/j.1552-4604.1984.tb01824.x","volume":"24","author":"VR Sheidler","year":"1984","unstructured":"Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD (1984) Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol 24(4):155\u2013159","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"9251_CR32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/j.1552-4604.1984.tb02756.x","volume":"24","author":"JE Stambaugh Jr","year":"1984","unstructured":"Stambaugh JE Jr, McAdams J, Vreeland F (1984) Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. J Clin Pharmacol 24(11):480\u2013485","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"9251_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00000421-198508000-00013","volume":"8","author":"A Niiranen","year":"1985","unstructured":"Niiranen A, Mattson K (1985) A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 8(4):336\u2013340","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"9251_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/adc.61.5.502","volume":"61","author":"AM Dalzell","year":"1986","unstructured":"Dalzell AM, Bartlett H, Lilleyman JS (1986) Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 61(5):502\u2013505","journal-title":"Arch Dis Child"},{"issue":"8","key":"9251_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/BF01728184","volume":"64","author":"N Niederle","year":"1986","unstructured":"Niederle N, Sch\u00fctte J, Schmidt CG (1986) Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 64(8):362\u2013365","journal-title":"Klin Wochenschr"},{"issue":"6","key":"9251_CR36","first-page":"946","volume":"79","author":"HS Chan","year":"1987","unstructured":"Chan HS, Correia JA, MacLeod SM (1987) Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79(6):946\u2013952","journal-title":"Pediatrics"},{"issue":"4","key":"9251_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/0277-5379(88)90300-8","volume":"24","author":"D Cunningham","year":"1988","unstructured":"Cunningham D, Bradley CJ, Forrest GJ et al (1988) A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24(4):685\u2013689","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"3","key":"9251_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00175407","volume":"6","author":"M McCabe","year":"1988","unstructured":"McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS (1988) Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 6(3):243\u2013246","journal-title":"Invest New Drugs"},{"issue":"6","key":"9251_CR39","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/00000421-199012000-00006","volume":"13","author":"M Lane","year":"1990","unstructured":"Lane M, Smith FE, Sullivan RA, Plasse TF (1990) Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 13(6):480\u2013484","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"9251_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/0885-3924(91)90026-Z","volume":"6","author":"M Lane","year":"1991","unstructured":"Lane M, Vogel CL, Ferguson J et al (1991) Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6(6):352\u2013359","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"9251_CR41","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1185\/030079907X167525","volume":"23","author":"E Meiri","year":"2007","unstructured":"Meiri E, Jhangiani H, Vredenburgh JJ et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23(3):533\u2013543","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"9251_CR42","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1365-2125.2010.03743.x","volume":"70","author":"M Duran","year":"2010","unstructured":"Duran M, P\u00e9rez E, Abanades S et al (2010) Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70(5):656\u2013663","journal-title":"Br J Clin Pharmacol"},{"key":"9251_CR43","unstructured":"Grimison P, Mersiades A, Kirby A, et al. 2024 Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II\/III trial. J ClinOncol. JCO2301836"},{"issue":"11","key":"9251_CR44","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","volume":"31","author":"P Grimison","year":"2020","unstructured":"Grimison P, Mersiades A, Kirby A et al (2020) Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 31(11):1553\u20131560","journal-title":"Ann Oncol"},{"issue":"23","key":"9251_CR45","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMra1402309","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Baler RD, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 370(23):2219\u20132227","journal-title":"N Engl J Med"},{"issue":"5","key":"9251_CR46","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/cpt.1381","volume":"105","author":"K Cohen","year":"2019","unstructured":"Cohen K, Weizman A, Weinstein A (2019) Positive and negative effects of cannabis and cannabinoids on health. Clin Pharmacol Ther 105(5):1139\u20131147","journal-title":"Clin Pharmacol Ther"},{"key":"9251_CR47","doi-asserted-by":"crossref","unstructured":"Machado Rocha FC, St\u00c9Fano SC, De C\u00c1Ssia Haiek R, Rosa Oliveira LMQ, Da Silveira DX. 2008 Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care. 17(5): 431-43","DOI":"10.1111\/j.1365-2354.2008.00917.x"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09251-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:36:09Z","timestamp":1742002569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09251-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9251"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09251-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}